Analysis

Gsk Plc (GSK) Stock Analysis

Gsk Plc investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to GSK.

websiteGSK/analysis/GSK

Gsk Plc

Gsk Plc investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to GSK.

Stock profile

Ticker

GSK

Asset type

Stock

Market cap

$101.77B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

GBX

Ticker listings

Gsk Plc may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • GSK primary listing
  • GS71
  • A3DMB5
  • GLAXF
  • GSKL
  • GSKD
  • G1SK34
  • GS70

Latest Gsk Plc news

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

PHILADELPHIA, June 17, 2026--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an...

GSK : Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK : Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections

Momelotinib orphan drug designations for VEXAS

GSK announced that its drug momelotinib has received Orphan Drug Designation from both the US FDA and the European Medicines Agency for the treatment of VEXAS syndrome, a rare a...

The Franklin Institute and GSK Celebrate 40 Years of GSK Science in the Summer™ with New "Be A Chemist!" Theme and Program Expansion

GSK Science in the Summer™, a free hands-on STEM enrichment program led by The Franklin Institute and supported by GSK, celebrates its 40th anniversary in 2026 with the launch o...

Nucala (mepolizumab) approved in Canada for use in adults with chronic obstructive pulmonary disease (COPD)

GSK announced today that Health Canada has approved Nucala (mepolizumab) as an add-on maintenance treatment in adult patients with COPD characterized by raised blood eosinophils...

Research sections

Valuation

Review valuation context for Gsk Plc.

Future growth

Review future growth context for Gsk Plc.

Past performance

Review past performance context for Gsk Plc.

Financial health

Review financial health context for Gsk Plc.

Dividend

Review dividend context for Gsk Plc.

Management

Review management context for Gsk Plc.

Ownership

Review ownership context for Gsk Plc.

Other information

Review other information context for Gsk Plc.

Community

Review community context for Gsk Plc.